Molecular Medicine and Biomedical Research in the Era of Precision Medicine

Dr. Ranbir Chander (RC) Sobti is Emeritus Professor at Punjab University, Chandigarh, and Honorary Scientist at the Indian National Science Academy. He started his career as a cytogeneticist and progressed to molecular biology and disease processes of cancer, COPD, AIDS, metabolic syndrome, and kidney diseases. He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases Royal Society of biology and international Association of Cancer Research. Dr. Sobti has participated in several book projects, including Elsevier’s Advances in Animal Experimentation and Modeling; Biomarkers in Cancer Detection and Monitoring of Therapeutics; Molecular Medicine and Biomedical Research in the Era of Precision Medicine; One Planet, One Health, One Future; Probiotics; and Public and Environmental Health. Dr Wilson’s career has spanned a number of decades and disciplines, from life as a junior chemist to academician at the University of Wales at Aberystwyth and Cardiff where he worked on diet and endocrinology. His early research emphasis was on cancer intervention using epidemiological evidence and related natural and synthetic products which has blossomed into works on phyto-oestrogens and flavonoids many of which form part of his several hundred publications. Chronomedicine also formed a major part of his work on breast cancer detection using thermorhythmometric procedures. He has 400-500 publications in biological sciences. In recognition of his contributions to science he has held senior positions in international and national organizations, memberships of many journal boards and is reviewer for many nutritional, statistical and cancer-related journals. He has been an invited global speaker at international events in USA, Asia and Europe and previously Australia and New Zealand. Harpal S. Buttar, PhD, is Adjunct Professor in the Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Canada, and also serves as Visiting Professor at Guru Nanak Dev University, India, and Honorary Professor at Amity University, India. He previously worked for more than four decades as a Senior Research Scientist and Assessment Officer in the Therapeutic Products Directorate of Health Canada. His research and professional interests include pharmacology, nutrition, functional foods, dietary interventions, lifestyle approaches to the prevention of cardiovascular disease, obesity, and diabetes, and the safety of drug interactions with herbal products and fruit juices. Dr. Buttar has contributed extensively to biomedical research through scholarly publications, book chapters, and international collaborations. He has served on the editorial boards of scientific journals, acted as an external examiner for postgraduate research degrees, and delivered invited lectures and seminars internationally. He is a Fellow of the International College of Nutrition and the International Academy of Cardiovascular Sciences.Dr. Télessy is a retired associate professor at the University of Pécs (2008) and University of Szeged (2002). He is a specialist in pharmacology and clinical and hospital pharmacy. His main research activity has been in the fields of clinical nutrition and clinical pharmacy. He has published more than 90 papers, written two books (single author) and contributed 6 book chapters.Dr. Télessy worked as pharmacist in public pharmacy for 20 years), in the pharmaceutical industry for 18 years and health authority for 5 years. He is fellow of numerous societies and led the Public Pharmacy Advisory Board of the Minister of Healthcare for 13 years. He was Vice President of the Hungarian Society of Pharmaceutical Sciences and also played a role as lecturer in ESPEN International Expert Courses in Clinical Nutrition for Pharmacy. Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).

• Section I: Introduction to molecular medicine, drug discovery and drug delivery, and their roles in biomedical sciences Introduction and PrefaceSection II: Technologies in biomedicine and molecular medicineA: Basic and emerging technologies1. Single-cell RNA-seq technologies in biomedical studies and their potential clinical applications2. Next-generation sequencing (NGS), OMICS and gene editing technologies: Their role in biomedical sciences3. Artificial intelligence in molecular medicine4. Role of modern scientific technologies and innovations for augmenting health care and precision in health care system5. Machine Learning in the field of health care using medical images6. Role of computer assisted prediction models in disease prevention7. Physiological studies on the usefulness of chips8. Bioinformatics as a tool for biomedical innovations9. Molecular Epidemiological approach in disease management10. Novel aspects of personalized medicines, patient care and management11. Stem cells and Gene Therapy in disease management12. Role of telemedicine in point of care treatment of patientsB: Application of technology in some diseases13. Machine learning based data modeling for heart disease prediction14. Computational biomedical sciences for renal disease management15. Impact of machine learning in the prediction and prevention of neurological diseases.16. Telemedicine and internet-based advice to pregnant and nursing mothers17. Effectiveness of telemedicine and internet-based diagnosis for the prevention of adverse drug effects (ADRs).18. Harvesting and growing of stem cells for regenerative medicine with special reference to dermal disorders19. Nanotechnology innovations for targeted delivery of multiple drugs in cancer patients20. Development of prolonged drug delivery systems for the treatment of chronic diseases21. Gold nanoparticles: A promising molecular probe for diagnostic purposes, discovery of new therapies, cure for certain cancers, as well as gene carriers and drug delivery vehicles22. Impact of circadian rhythms in neurological disorders, cardiovascular diseases, and diabetes mellitus23. Role of Omics and metabolomics in drug discovery and drug delivery in biomedical sciences24. Pharmacogenetics in drug dose adjustments in the pediatric and elderly populations25. Impact of lifestyle factors on cognitive function in older adults (> 60 yrs.) and detection by apolipoprotein E genotyping.Section III: Interventions and treatments across disease typesA: Role of microbiota in diseases26. Pivotal role of healthy gut microbiota in the prevention of non-communicable diseases (NCDs)27. Emerging role of gut microbiomes in immunomodulation and colorectal cancer28. Influence of the gut microbiomes on cardiovascular health and hypertension29. Role of probiotics, prebiotics and symbiotic in the improvement of gut microflora30. Genetic, cellular and molecular biology germane to cardiovascular ailments (e.g., coronary heart disease and stroke) and neurological diseases (e.g., dementia, Alzheimer disease) in the ageing population31. Molecular biology of chronic heart failure: Prevention and management by antioxidant and anti-inflammation foods and phytotherapies32. Therapeutic applications of human and bovine colostrum: Underlying mechanisms of actionB: Challenges and interventions in NCDs33. Environmental impact on cardiorespiratory and kidney related diseases34. Pathophysiology of coronary heart disease: Role of the renin-angiotensin and aldosterone system35. Emerging respiratory problems including chronic obstructive pulmonary disease (COPD)36. Stroke: Causes, diagnosis and management by cholesterol lowering agents and other suitable medicinesC: Challenges and interventions in infectious diseases37. Emerging and re-emerging infectious diseases and challenges ahead38. Tuberculosis: Molecular aspects in prediction, diagnosis and treatment39. Viral hepatitis: its occurrence, diagnosis and management40. Monkey pox and its impact on human health41. Prophylactic vaccination strategies for the prevention of microbial diseases with particular reference to COVID-19 on public health and health care systemSection IV: Molecular medicine and nutrition42. Clinical Nutrition in health promotion and well-being43. Influence of nutraceuticals in health promotion and disease prevention44. Biochemical, biophysical and therapeutic properties of functional foods and Mediterranean diet45. Traditional and novel fermented foods in the prevention of non-communicable diseases (NCDs)46. Clinical implications and mechanism of drug-drug and drug-food-herbal interactions​​​​​​​Section V: Targeted therapies and strategies for the treatment of acute and chronic diseases47. Emerging trends in drug delivery systems: Scope and challenges48. Role of Nanotechnology in the targeted delivery of anticancer drugs49. Impact of Phamacometabolomics in new drug discovery and development of novel therapies for the management of NCDs50. Drug dose adjustment in elderly population using polypharmacy for co-morbid conditions51. Safety and efficacy assessment of new vaccines and their development52. Antibiotic resistance and development alternative therapies53. Drug regulatory requirements by the drug regulatory agencies54. Post-marketing surveillance of drugs for monitoring adverse drug reaction (ADRs)55. Ethical issues and challenges in biomedical researchSection VI: Future perspectives in the development of novel technologies in biomedicine and molecular medicine

Select Guide Rating